Fig. 5

Intranasal delivery of hMSCs promotes N2 polarization of neutrophils in the brain after stroke. A: Proportion of CD45^highCD11b⁺Ly6G⁺CD206⁺ N2 subtype neutrophils in the brain treat with hMSC-L and hMSC-M. B, C: CD45⁺CD11b⁺Ly6G⁺CD206⁺ neutrophils in peripheral blood (B) and bone marrow (C) following hMSC-L and hMSC-M treatment. D: qPCR analysis of NE, MPO and PADi4 mRNA expression in brain tissues after ischemic stroke treated with hMSC-L and hMSC-M. E: qPCR analysis of VEGF, TGF-β and IL-10 mRNA expression in brain tissues after ischemic stroke treated with hMSC-L and hMSC-M. n = 5, vs MCAO, ns no significance; ^*P < 0.05, ^**P < 0.01, ^***P < 0.001. hMSC-L vs hMSC-M ns no significance; ^#P < 0.05, ^##P < 0.01